Skip to main content

Axis Bank Q1 profit falls 19% to Rs 1,112 crore, NII grows 19.5%; slippages decline

Date - 21/07/2020

Net interest income grew by 19.5 percent year-on-year to Rs 6,985.3 crore in the quarter ended June 2020.

 

The country's third-largest private sector lender Axis Bank has reported an 18.8 percent year-on-year decline in standalone profit for the June quarter, impacted by lower other income and higher provisions.

Profit during the quarter declined to Rs 1,112.17 crore compared to Rs 1,370.08 crore in the corresponding period last year.

Net interest income (NII) grew by 19.5 percent year-on-year to Rs 6,985.3 crore in the quarter, with a strong loan growth of 17 percent (including TLTRO investments) and deposits growth of 19 percent on quarterly average basis (QAB).

The private lender's savings account deposits grew 15 percent YoY, current account deposits 8 percent and retail term deposits (RTD) were up 27 percent on QAB basis, while including TLTRO (Targeted Long Term Repo Operations) investments, corporate loans grew 26 percent and retail loans 16 percent.

 

Other income or non-interest income (comprising fee, trading profit and miscellaneous income) for Q1FY21 declined 33.1 percent to Rs 2,587 crore YoY as fee income fell 38 percent YoY to Rs 1,651 crore, the bank said. The bank attributed the decline in fees to lower business volumes and velocity of throughput of transactions.

Pre-provision operating profit (PPoP) declined 0.8 percent to Rs 5,844.4 crore compared to the corresponding quarter of the last fiscal.

"Adjusted for accounting policy changes and NII reserves created during the quarter, NII, operating profit and PAT for the quarter would have been Rs 7,100 crore, Rs 6,151 crore and Rs 1,626 crore, respectively, growing by 22 percent, 4 percent and 19 percent YoY, respectively," Axis Bank said in its BSE filing.

Asset quality has seen improvement on sequential as well as yearly basis. Gross non-performing assets as a percentage of gross advances declined 14 bps QoQ to 4.72 percent and net NPAs dropped 33 bps QoQ to 1.23 percent in June quarter 2020.

Axis Bank said it recognised slippages of Rs 2,218 crore during Q1FY21, compared to Rs 3,920 crore in Q4FY20.

"Slippages from the loan book were at Rs 2,011 crore and that from investment exposures stood at Rs 207 crore. Corporate slippages stood at Rs 1,355 crore. Recoveries and upgrades from NPAs during the quarter were Rs 608 crore while write-offs were Rs 2,284 crore," it added.


Provisions and contingencies were higher by 15.8 percent to Rs 4,416.42 crore at the end of June quarter 2020, but were lower by 42.9 percent compared to the March quarter.

The bank said it had made incremental provisions of Rs 733 crores in Q1 FY21 towards COVID-19. "In June 2020, the bank holds in aggregate additional provisions of Rs 6,898 crore. It is pertinent to note that this is over and above the NPA provisioning included in our PCR calculations, and the 0.4 percent standard asset provisioning requirement on standard assets."

Source - Moneycontrol


Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more